Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck
Griffin S, Walker S, Sculpher M, White S, Erhorn S, Brent S, Dyker A, Ferrie L, Gilfillan C, Horsley W, Macfarlane K, Thomas S
Record ID 32010001447
English
Authors' recommendations:
A number of areas of uncertainty emerged in the manufacturer’s cost-effectiveness modelling. These relate mainly to the extrapolation methods and the assumptions used to derive the utility and cost estimates. However, based on the sensitivity analyses undertaken by the manufacturer and some additional ERG analyses, these areas of uncertainty are unlikely to have a material effect on the conclusions of the cost-effectiveness analysis. Future research into establishing which patients are likely to derive most benefit from cetuximab in conjunction with radiotherapy would be useful, as would further research on the clinical effectiveness of cetuximab plus radiotherapy in those patients with locally advanced SCCHN who are considered inappropriate for chemoradiotherapy. Setting up a patient register to collect post-treatment observational data of patients treated withcetuximab may be useful.
Details
Project Status:
Completed
URL for project:
http://www.hta.ac.uk/1642
Year Published:
2009
URL for published report:
n/a
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antibodies, Monoclonal, Humanized
- Cetuximab
- Antineoplastic Agents, Immunological
- Radiotherapy
- Head and Neck Neoplasms
- Squamous Cell Carcinoma of Head and Neck
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.